cyclobenzaprine hydrochloride

PreclinicalSmall molecule

cyclobenzaprine hydrochloride is one of 32 small molecule programs targeting Fasting Conditions. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fasting ConditionsCompleted

Temporomandibular DisordersCompleted

Fasting ConditionsPreclinical

Completed

Temporomandibular DisordersPreclinical

Completed

Competition

Competitive Landscape

35 competitors in Fasting Conditions

#DrugCompanyPhaseTrials

Dynastat

Pfizer

Phase 3

1 2

Flomax

Sanofi

Phase 1

2 3

Jardiance

Boehringer Ingelheim

Phase 1

4 4

Lamisil

Novartis

Preclinical

1 5

Monopril

Bristol-Myers Squibb

Preclinical

1 6

Ambien

PPurdue Pharma LP

Preclinical

4 7

Jardiance

Boehringer Ingelheim

Phase 1

1 8

Anjeso

Boehringer Ingelheim

Preclinical

3 9

Isopto Carpine

AAdvanz Pharma

Preclinical

2 10

Plendil

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Migraine1 trial

Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine

Terminated·KKennedy Medical Group·Phase 3·NCT01151787·35 enrolled

Muscle spasm1 trial

An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm

Completed·MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.·Phase 4·NCT00246389·1,000 enrolled

Cognitive Function1 trial

Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

Completed·NNeurana Pharmaceuticals, Inc.·Phase 1·NCT04407377·39 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Cyclobenzaprine Hydrochloride 10 mg Tablets, USP Under Fasting Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT00778037·40 enrolled

Temporomandibular Disorders1 trial

Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders

Completed·IInstituto Brasileiro de Osteopatia·N/A·NCT02974166·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for cyclobenzaprine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cyclobenzaprine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cyclobenzaprine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurana Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNeurana Pharmaceuticals, Inc.

cyclobenzaprine hydrochloride

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Migraine1 trial

Muscle spasm1 trial

Cognitive Function1 trial

Fasting Conditions1 trial

Temporomandibular Disorders1 trial

References

Drug Info

Quick Facts

Related News